VIDA CEO Susan Wood presents at the LSI Emerging Medtech Summit to explain how the lung has been underfunded because lung trials are slow and very costly which disincentives investment.
VIDA is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal.
VIDA Diagnostics, Inc. ("VIDA"), the leader in lung and respiratory intelligence, announced today that it is has appointed Karen Drexler to its board of directors
In the wake of the Covid-19 pandemic we all can feel lost, helpless and bereft of hope at times. We turn on the news to see conflicting “experts” telling us to do opposite things for the sake of our health and the public’s health.
The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2020.
Blue Heron Capital, a Richmond, Virginia-based growth equity fund, announced today its participation in an $11 million investment round in VIDA Diagnostics, Inc.